Summary:
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination with GLP-1 RA in Patients with Type 2 Diabetes
Criteria:- Be 20-75 years old
- Be diagnosed type 2 diabetes
- Be overweight
- Additional criteria apply
Qualified Participants May Receive:
- Study-related care at no cost
- Compensation up to $5,625 for time and trial-related travel expenses